Previous 10 | Next 10 |
The FDA grants Breakthrough Therapy Designation to PolyPid's (PYPD) lead product candidate D-PLEX100 for the prevention of post-abdominal surgery incisional infection (soft tissue).Breakthrough Therapy status provides for more intensive guidance from the FDA on development...
PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX ...
PolyPid Ltd. (PYPD) Q3 2020 Earnings Conference Call November 11, 2020 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Akselbrad - Executive Vice President and Chief Financial Officer Conference Call Participants Gary Nachman - BMO Ca...
PolyPid (PYPD): Q3 GAAP EPS of -$0.35.Cash, cash equivalents and short term deposits of $43.7MPress Release For further details see: PolyPid reports Q3 results
• Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval • Phase 3 SHIELD II t rial a ...
PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announce...
PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announce...
PolyPid Ltd. (PYPD) Q2 2020 Results Conference Call August 19, 2020 08:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Czaczkes - Executive Vice President and Chief Financial Officer Taunia Markvicka - Chief Operating Off...
PolyPid (NASDAQ: PYPD ) : Q2 Non-GAAP net loss of $4.8M; GAAP net loss of $19.1M. More news on: PolyPid Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Initiated Phase 3 SHIELD I Trial for D-PLEX 100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX 100 from FDA Presented Positive Phase 2 Results of D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery at ASCRS Meeting Completed Initial...
News, Short Squeeze, Breakout and More Instantly...
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned...
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections ; Recruitment Expected to Re sume Imminently Received Advice from the Swedish Medical Prod...
PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results...